O
EW icon

OrbiMed’s Edwards Lifesciences EW Stock Holding History

OrbiMed’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$98.5M Sell
1,230,600
-612,300
-33% -$50.5M 1.95% 14
2025
Q4 		$157M Buy
1,842,900
+158,900
+9% +$13M 3.21% 5
2025
Q3 		$131M Sell
1,684,000
-24,000
-1% -$1.88M 3.08% 8
2025
Q2 		$134M Buy
1,708,000
+176,000
+11% +$13.1M 3.34% 9
2025
Q1 		$111M Buy
1,532,000
+386,698
+34% +$27.7M 2.65% 9
2024
Q4 		$84.8M Buy
+1,145,302
New +$80.2M 1.74% 17
2023
Q3 		– Sell
-515,000
Closed -$48.6M – 131
2023
Q2 		$48.6M Sell
515,000
-115,000
-18% -$10M 0.88% 42
2023
Q1 		$52.1M Sell
630,000
-230,500
-27% -$18.1M 1.02% 33
2022
Q4 		$64.2M Sell
860,500
-105,800
-11% -$8.15M 1.23% 28
2022
Q3 		$79.8K Sell
966,300
-45,000
-4% -$4.33M 1.48% 24
2022
Q2 		$96.2K Sell
1,011,300
-40,000
-4% -$4.14M 1.74% 21
2022
Q1 		$124M Sell
1,051,300
-24,900
-2% -$2.79M 2.01% 16
2021
Q4 		$139M Sell
1,076,200
-50,200
-4% -$5.86M 1.79% 14
2021
Q3 		$128M Hold
1,126,400
– – 1.4% 23
2021
Q2 		$117M Hold
1,126,400
– – 1.18% 29
2021
Q1 		$94.2M Buy
1,126,400
+100,600
+10% +$8.5M 0.88% 35
2020
Q4 		$93.6M Buy
1,025,800
+319,300
+45% +$26.5M 0.82% 37
2020
Q3 		$56.4M Buy
706,500
+176,100
+33% +$13.7M 0.71% 41
2020
Q2 		$36.7M Hold
530,400
– – 0.52% 57
2020
Q1 		$33.3M Sell
530,400
-774,300
-59% -$55.8M 0.56% 48
2019
Q4 		$101M Sell
1,304,700
-218,700
-14% -$17.1M 1.45% 19
2019
Q3 		$112M Sell
1,523,400
-621,600
-29% -$43.7M 2.12% 11
2019
Q2 		$132M Hold
2,145,000
– – 2.05% 12
2019
Q1 		$137M Buy
2,145,000
+748,200
+54% +$42.7M 2.12% 11
2018
Q4 		$71.3M Sell
1,396,800
-1,575,000
-53% -$79.7M 1.32% 23
2018
Q3 		$172M Buy
2,971,800
+359,100
+14% +$17.6M 2.08% 12
2018
Q2 		$127M Sell
2,612,700
-461,100
-15% -$21.5M 1.51% 18
2018
Q1 		$143M Sell
3,073,800
-298,500
-9% -$13M 1.77% 17
2017
Q4 		$127M Sell
3,372,300
-799,800
-19% -$29.4M 1.6% 20
2017
Q3 		$152M Sell
4,172,100
-1,345,800
-24% -$51.3M 1.45% 23
2017
Q2 		$217M Hold
5,517,900
– – 2.28% 12
2017
Q1 		$173M Buy
5,517,900
+1,463,700
+36% +$45.8M 1.96% 13
2016
Q4 		$127M Sell
4,054,200
-65,400
-2% -$2.12M 1.61% 21
2016
Q3 		$166M Buy
4,119,600
+2,585,400
+169% +$97.4M 1.89% 14
2016
Q2 		$51M Buy
1,534,200
+1,189,200
+345% +$40.7M 0.53% 51
2016
Q1 		$10.1M Buy
+345,000
New +$9.52M 0.11% 93
2013
Q4 		– Sell
-300,000
Closed -$3.48M – 130
2013
Q3 		$3.48M Hold
300,000
– – 0.06% 111
2013
Q2 		$3.36M Buy
+300,000
New +$3.55M 0.07% 114

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OrbiMed's EW Position: Q1 2026 in Review

OrbiMed reduced its Edwards Lifesciences (EW) stake by 33% in Q1 2026, selling an estimated $50.5M and leaving 1,230,600 shares worth $98.5M. The position accounts for 1.95% of the portfolio, ranked #14.

OrbiMed first reported a position in EW in Q2 2013 and has held it in 38 quarters since. The position peaked at $217M in Q2 2017. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • OrbiMed held 1,230,600 shares of Edwards Lifesciences worth $98.5M as of Q1 2026.
  • OrbiMed sold 612,300 Edwards Lifesciences shares in Q1 2026, an estimated $50.5M.
  • Edwards Lifesciences made up 1.95% of OrbiMed's portfolio in Q1 2026, its #14 holding.
  • OrbiMed first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 38 quarters since.
  • OrbiMed's Edwards Lifesciences position peaked at $217M in Q2 2017.
  • 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.